Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Solvay discontinues R&D activities of antiobesity compound SLV-319

Nov. 18, 2008

Recent University of Aberdeen patent discloses novel agents for bone disorders

Nov. 18, 2008

Pooled GOUT 1 and GOUT 2 data detail effects of pegloticase

Nov. 18, 2008

New antidiabetic agents disclosed in recent patent literature

Nov. 17, 2008

Novel compounds for lipoprotein disorders described in recent patents

Nov. 17, 2008

IRM reports novel antiobesity compounds in a recent patent

Nov. 14, 2008

FDA designates as complete AMAG's resubmission for ferumoxytol NDA in CKD

Nov. 14, 2008

Affymax completes enrollment in EMERALD 1 phase III clinical trial of Hematide

Nov. 14, 2008

FDA approves low-dose Premarin regimen to treat postmenopausal dyspareunia

Nov. 14, 2008

Novel antiobesity agents disclosed in recent patents

Nov. 13, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 19, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
Authorities work to quickly sequence Ebola species in latest outbreak
BioWorld
If the recent hantavirus outbreak wasn’t enough to keep public health officials busy, a new Ebola virus disease outbreak has been confirmed by authorities in the...
Camp4 studies CMP-002 in SYNGAP1 haploinsufficient mouse model
BioWorld Science
Camp4 Therapeutics Corp. has highlighted new preclinical data for CMP-002, the company’s lead investigational antisense oligonucleotide (ASO) therapeutic...